Role of erythropoietin in the treatment of lung cancer associated anaemia
- 1 December 2001
- journal article
- review article
- Published by Elsevier in Lung Cancer
- Vol. 34, 91-94
- https://doi.org/10.1016/s0169-5002(01)00398-1
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapyBritish Journal of Cancer, 2000
- The impact of radiation related factors upon long term outcome in the management of advanced head and neck (H/N) squamous cell carcinoma (SCCa) treated with supradose intra-arterial targeted (SIT) cisplatin (P) and radiation therapy (RT)International Journal of Radiation Oncology*Biology*Physics, 1998
- Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.Journal of Clinical Oncology, 1998
- Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.Journal of Clinical Oncology, 1997
- Cisplatin-associated anemia: an erythropoietin deficiency syndrome.Journal of Clinical Investigation, 1995
- The Frequency of Red Cell Transfusion for Anemia in Patients Receiving Chemotherapy A Retrospective Cohort StudyAmerican Journal of Clinical Oncology, 1993
- Radiotherapy and anaemia — the clinical experienceRadiotherapy and Oncology, 1991
- Erythropoiesis, erythropoietin, and ironBlood, 1982